Cancer Pain Market

• Pain is common in cancer patients, particularly in the advanced stage of the disease, contributing to poor physical and emotional well-being.
• Younger individuals are more likely to experience cancer pain, and people with advanced cancer experience more severe pain. Cancer causes pain often due to a tumor pressing on other organs, bones, or nerves.
• Opioid-based treatments are the mainstay of moderate-to-severe cancer-related pain. The goal of long-term opioid treatment is to provide sustained, clinically meaningful relief of pain with tolerable side effects and an overall benefit to the quality of life.
• In the 7MM, the US accounted for the highest number of cases of cancer pain with nearly 2,400,000 in 2023.
• Among the current Cancer Pain Therapies, adjuvant analgesics account for the largest market size, followed by strong opioids
• Some promising Cancer Pain Emerging Therapies are- QIXLEEF (Tetra Bio-Pharma), Halneuron (WEX Pharmaceuticals), and others.
• The Cancer Pain Market is anticipated to witness a substantial positive shift owing to the expected market launch of coming therapies and raised awareness.

Request for unlocking the sample page of the "Cancer Pain Treatment Market"

DelveInsight's “Cancer Pain Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Cancer Pain, historical and forecasted epidemiology as well as the Cancer Pain market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Cancer Pain Treatment Market Report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM cancer pain market size from 2020 to 2034. The report also covers current cancer pain treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Cancer Pain Treatment Market: Understanding and Algorithm

Cancer Pain Overview, Country-Specific Treatment Guidelines and Diagnosis

Pain is prevalent in cancer patients, especially in advanced stages, and impacts both physical and emotional well-being. It can stem from tissue damage caused by tumors or treatment-related factors like surgery, chemotherapy, immunotherapy, or radiation therapy. Healthcare providers assess the pain by asking about its location, characteristics, onset, and factors that alleviate or exacerbate it. They may use pain scales ranging from 0 to 10 or visual representations to gauge its intensity. Diagnostic imaging like X-rays, CT scans, or MRIs might be used to identify the underlying cause, potentially requiring contrast agents. Stimulation tests such as nerve conduction studies or muscle function tests can pinpoint affected nerves or muscles. 

Further details related to country-based variations in diagnosis are provided in the report

Cancer Pain Treatment

Non-opioids are recommended for mild pain, with the addition of mild opioids for moderate pain and strong opioids for severe pain. Several drugs besides non-opioids and opioids have been found to provide pain relief in specific situations. They include antidepressants, anticonvulsants, and steroids. These drugs are being used with excellent results to manage cancer-related pain. Some of them have been found to help relieve certain types of pain. For example, tingling and burning sensations and pain caused by inflammation (swelling) can be treated by adjuvant analgesics. 

Cancer Pain Epidemiology

The cancer pain epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. The cancer pain epidemiology is segmented with detailed insights into Total Cases of Cancer Pain, Etiology-specific Cases of Cancer Pain, Incidence of Chemotherapy-Induced Peripheral Neuropathy, Severity-specific Cases of Cancer Pain, Pathophysiology-specific Cases of Cancer Pain, Temporal Variation-specific Cases of Cancer Pain, and Incidence of Breakthrough Cancer Pain (BTcP).

• In the 7MM, the US accounted for the highest number of cases of cancer pain with nearly 2,400,000 in 2023.
• Among the etiology-specific cases, the cases of direct tumor involvement accounted for nearly 1,470,000 in the US in 2023.
• Among EU4 and the UK, Germany accounted for the highest incident cases of chemotherapy-induced peripheral neuropathy in 2023.
• Among the pathophysiology-specific cases, the cases of nociceptive pain accounted for the highest number.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Cancer Pain Prevalence

Cancer Pain Drug Chapters

The drug chapter segment of the cancer pain therapeutics market report encloses a detailed analysis of cancer pain-marketed drugs and late-stage (Phase III and Phase II) Cancer Pain pipeline drugs analysis. It also deep dives into the pivotal cancer pain clinical trials details, recent and expected market approvals, patent details, the latest Cancer Pain news, and recent deals and collaborations. 

Cancer Pain Emerging Drugs

• Halneuron (Tetrodotoxin or TTX): WEX Pharmaceuticals 

Tetrodotoxin (TTX) blocks the voltage-gated sodium channels (VGSCs) found on nerves that conduct pain impulses, which are known to be affected in chronic pain conditions. Halneuron is an injectable formulation of tetrodotoxin, a novel small molecule with action on the peripheral nervous system. WEX is conducting clinical trials for Halneuron to treat cancer-related pain and chemotherapy-induced neuropathic pain. Initial data shows varying levels of pain relief, prompting the launch of a pivotal Phase III trial in the United States for chemotherapy-induced neuropathic pain. Additionally, Phase III trials for cancer-related pain are underway in other regions.

Get More Insights @ Halneuron Market

• QIXLEEF: Tetra Bio-Pharma

PPP011/QIXLEEF, developed by Tetra Bio-Pharma, is an innovative botanical inhaled drug product designed to provide fast relief from pain without the use of opioids. It is undergoing evaluation in two Phase II trials. The REBORN trial compares its efficacy against opioid treatment for breakthrough pain in cancer patients, while the PLENITUDE trial assesses its safety and efficacy for uncontrolled pain relief in advanced cancer patients. Positive initial clinical data from these trials were announced in November 2021. In March 2022, Tetra Bio-Pharma received guidance from the US FDA regarding the nonclinical safety program required for a marketing application.

Note: Detailed emerging therapies assessment will be provided in the final report.

Cancer Pain Market Outlook

Opioid-based treatments are the mainstay of moderate-to-severe cancer-related pain. The goal of long-term opioid treatment is to provide sustained, clinically meaningful relief of pain with tolerable side effects and an overall benefit to the quality of life. There are several non-opioid treatment modalities available to patients. These include both pharmacologic and non-pharmacologic strategies. Acetaminophen has been used as a first-line treatment in patients with mild cancer pain who may not require an opioid or may be hesitant to use an opioid. Nonsteroidal anti-inflammatory drugs (NSAIDs) have anti-inflammatory, analgesic, and antipyretic properties.

This class of medications has a maximum daily dose and multiple safety considerations. Adjuvants are medications used for managing nociceptive pain and may have an additive effect when combined with opioids or may be used as single agent treatment for managing neuropathic pain. Two common classes of adjuvant medications include antidepressants and anticonvulsants. 

Currently, there are many barriers to adequate pain management. Although they are not specific to cancer-related pain, the societal changes that occurred and are subsequently outlined have still impacted patients with chronic nonmalignant and cancer-related pain. The poor reimbursement for these clinics under fee-for-service models, an increase in managed care, rising financial pressures in medical centers, and a focus on procedure-based interventions for physicians’ pain management training all burdened the growth of these valuable practices. Key Cancer Pain Companies, such as Terta Bio-pharma, WEX Pharmaceuticals, Intellia Therapeutics, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of cancer pain. Therefore, with the rising patient population and the expected launch of emerging therapies, it is safe to assume that the market will be uplifted and undergo a positive boost during the study period.

• In the 7MM, the US accounted for the largest Cancer Pain Treatment Market Size with nearly USD 1,680 million in 2023.
• Among EU4 and the UK, Germany has the largest Cancer Pain Market Size followed by France. Spain has the lowest market size.
• Among the current therapies, adjuvant analgesics account for the largest Cancer Pain Market Size, followed by strong opioids.

Cancer Pain Drugs Uptake

This section focuses on the uptake rate of potential Cancer Pain drugs expected to be launched in the market during 2024–2034, which depends on the Cancer Pain competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key Cancer Pain Companies evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Further detailed analysis of emerging therapies drug uptake in the report…

Cancer Pain Pipeline Development Activities

The Cancer Pain therapeutics market report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key Cancer Pain Companies involved in developing targeted therapeutics. 

Pipeline Development Activities

The Cancer Pain therapeutics market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Cancer Pain emerging therapies. 

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Cancer Pain. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Cancer Pain Drugs Market: Qualitative Analysis

We perform Qualitative and Cancer Pain Drugs Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, Cancer Pain Competitive Landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Cancer Pain Therapeutics Market Access and Reimbursement

The Cancer Pain therapeutics market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Cancer Pain Treatment Market Report Scope

• The Cancer Pain therapeutics market report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country-specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Cancer Pain treatment market, historical and forecasted Cancer Pain treatment market size, Cancer Pain drugs market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Cancer Pain therapeutics market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Cancer Pain drugs market.

Cancer Pain Therapeutics Market Report Insights

• Patient-based Cancer Pain Market Forecasting
• Therapeutic Approaches
• Cancer Pain Pipeline Drugs Analysis
• Cancer Pain Market Size and Trends
• Existing and future Cancer Pain Drugs Market Opportunity 

Cancer Pain Therapeutics Market Report Key Strengths

• 11 Years Cancer Pain Market Forecast
• 7MM Coverage 
• Cancer Pain Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on approved and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Cancer Pain Drugs Uptake
• Key Cancer Pain Market Forecast Assumptions

Cancer Pain Therapeutics Market Report Assessment

• Current Cancer Pain Treatment Market Practices
• Cancer Pain Unmet Needs
• Cancer Pain Pipeline Drugs Profiles
• Cancer Pain Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the growth rate of the 7MM Cancer Pain treatment market?
• What was the Cancer Pain treatment market size, the Cancer Pain market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the Cancer Pain market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Cancer Pain? 
• How many Cancer Pain Companies are developing therapies for the Cancer Pain Treatment?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to Buy

• The Cancer Pain therapeutics market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Cancer Pain Drugs Market.
• Insights on patient burden/disease Cancer Pain Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Cancer Pain Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Cancer Pain Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Stay Updated with us for Recent Articles

• Cancer Care In The Time Of COVID
• Cancer In The United States(Vol 1, Issue 2)
• Latest DelveInsight Blogs